A Thousand Tiny Pieces: The Federal Circuit’s Fractured Myriad Ruling, Lessons to Be Learned, and the Way Forward

24 Pages Posted: 22 Apr 2012  

Jonathan Stroud

Unified Patents Inc.

Date Written: September 20, 2011

Abstract

The Supreme Court granted, vacated, and remanded the infamous Ass’n of Molecular Pathology v. U.S. Patent & Trademark Office (Myriad I), gene-isolation patentability case to the Court of Appeals for the Federal Circuit (CAFC) in light of the recent Prometheus decision, which held 9-0 that a certain diagnostic method was invalid subject matter because it was an abstract idea merely modified by other obvious steps. This Article argues that Myriad should be affirmed again by the Federal Circuit, particularly in light of Prometheus, in order to inject certainty, clarity, and consistency into the § 101 patentable subject matter jurisprudence.

Keywords: Myriad, Genetics, Diagnostics, Patents, Subject-Matter, 101, Prometheus, GVR, FDA, Court of Appeals for the Federal Circuit, Federal Circuit, AMP v. USPTO

Suggested Citation

Stroud, Jonathan, A Thousand Tiny Pieces: The Federal Circuit’s Fractured Myriad Ruling, Lessons to Be Learned, and the Way Forward (September 20, 2011). IP Theory, Vol. 3, 2012; American University, WCL Research Paper. Available at SSRN: https://ssrn.com/abstract=2043263

Jonathan Stroud (Contact Author)

Unified Patents Inc. ( email )

171 Main St. #106
Los Altos, CA 94022
United States
202-805-8931 (Phone)

HOME PAGE: http://unifiedpatents.com

Paper statistics

Downloads
57
Rank
307,312
Abstract Views
813